Phase I study of inotuzumab ozogamicin (INO) combined with R-GDP for relapsed CD22+ B-cell non-Hodgkin lymphoma (B-NHL).
Randeep S. Sangha
No relevant relationships to disclose
Andrew John Davies
Research Funding - Pfizer
Nam H. Dang
Honoraria - Pfizer
Research Funding - Pfizer
Michinori Ogura
Research Funding - Pfizer
M. Luisa Paccagnella
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Revathi Ananthakrishnan
Employment or Leadership Position - Pfizer
Erik Vandendries
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Goh Yeow Tee
No relevant relationships to disclose